Jazz Pharmaceuticals PLC (NAS:JAZZ)
$ 109.74 -2.27 (-2.03%) Market Cap: 6.92 Bil Enterprise Value: 11.03 Bil PE Ratio: 22.63 PB Ratio: 1.87 GF Score: 78/100

Q1 2021 Jazz Pharmaceuticals PLC Earnings Call Transcript

May 04, 2021 / 08:30PM GMT
Release Date Price: $160.2 (-2.99%)
Operator

Welcome to the Jazz Pharmaceuticals plc First Quarter 2021 Earnings Conference Call. (Operator Instructions)

I will now turn the call over to Andrea Flynn, Head of Investor Relations to Jazz Pharmaceuticals. Thank you. Please go ahead.

Andrea N. Flynn
Jazz Pharmaceuticals plc - VP & Head of IR

Thank you, and good afternoon, everyone. Today, we reported our first quarter 2021 financial results. The press release and slide presentation accompanying this webcast are available on the Investors section of our website.

On the call today are Bruce Cozadd, Chairman and Chief Executive Officer; Renee Gala, Executive Vice President and Chief Financial Officer; Dan Swisher, President and Chief Operating Officer; and Rob Iannone, Executive Vice President, R&D and Chief Medical Officer. Joining the Q&A are Kim Sablich, Executive Vice President, General Manager of North America; Phil Jochelson, Neuroscience Therapeutic Head; and Anne Borgman, Hematology and Oncology Therapeutic Head.

On Slides 2 and 3, I'd like to remind you that

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot